Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
In POSITIVE study, menstruation resumptions occurred mostly during the first 6 months, with young age being the most determinant factor
Evidence for efficacy is based on the results from the IMerge study
Findings from the CONTINUUM study
It is intended for the first-line treatment of patients with metastatic non-oncogene addicted NSCLC in combination with platinum-based chemotherapy
Findings from the MOTION study
Findings from the HARMONi-A study
It is the first FDA approval of a targeted therapy for paediatric patients with RET alterations
Findings from the ASC4FIRST study
New indication concerns combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with advanced NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations
Findings from the NETTER-2 study
Findings from the NICHE-2 study
Evidence for efficacy is based on the results from the TRANSCEND-MCL study
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
